The ABC-03 trial

As a result of the landmark ABC-02 study, the Cisplatin and Gemcitabine chemotherapy combination1 is recognised as the standard first-line treatment for those with inoperable biliary tract cancer (cholangiocarcinoma).  However, the search goes on for improvements to this regime.

In the ABC-03 study, Cediranib (an anti angiogenic drug1) was added to the Gemcitabine / Cisplatin combination.

Unfortunately, this addition did not improve progression-free survival, but the results have shown there could still be an avenue worth pursuing with an agent other than Cediranib.

The findings of the ABC-03 randomised phase 2 trial have now been produced by Professor Juan Valle et al. and the article has been published in the August edition of The Lancet Oncology.


To read the article, “Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial” in full, click here

It is also very gratifying to see AMMF acknowledged in this work (under the Acknowledgements section at the very end of the article).


Professor Andrew Zhu (Harvard Medical School, USA) has commented on this work in an article also published in The Lancet Oncology.  To read this click here

ABC-03 at ASCO 2015

The ABC-03 poster was presented by Dr Alison Backen at ASCO 2015.

The ABC-03 poster:

1  To read more about ABC-02 and the Gemcitabine/Cisplatin chemotherapy combination, go to:

2 Anti angiogenic drugs – biological therapies that stop tumours from growing their own blood vessels.

August 2015